Medical imaging-based companion diagnostics for solid tumors  

作　　者：Rui Yin Qingpeng Zhang Shiyi Liao Chang Lu Cheng Zhang Qingyun Cai Guosheng Song 

机构地区：[1]State Key Laboratory for Chemo/Biosensing and Chemometrics,College of Chemistry and Chemical,Engineering,Hunan University,Changsha 410082,China

出　　处：《EngMedicine》2024年第1期70-86,共17页医工交叉（英文）

基　　金：supported by the National Natural Science Foundation of China[grant number U21A20287];the Shenzhen Science and Technology Program[grant number JCYJ20210324140205013].

摘　　要：Heterogeneity within the solid tumor microenvironment contributes to a poor prognosis and limited therapeutic responses.Companion diagnostics(CDx),a clinical technique that gives doctors vital biomarker information to enhance patient outcomes through matching specific treatments to patients,is becoming more and more important.However,most current US Food and Drug Administration(FDA)-approved CDx tests have difficulty dynamically reflecting variations in biomarkers in the solid tumor microenvironment because they are used in vitro and ex vivo.Consequently,new medical imaging-based CDx tests have been widely used to detect interpatient and intrapatient tumor heterogeneity to assess the intratumoral distribution of specific biomarkers and microenvironment variables.They provide patient stratification for targeted therapies and the differentiation of patient populations that benefit from alternative treatments.This review provides an overview of the recent advances in medical imaging-based CDx for solid tumors and summarizes the various tumor microenvironment biomarkers utilized in imaging-based CDx.We believe that this review offers additional details and directions for promoting medical imaging-based CDx development.

关 键 词：IMAGING Biomarkers Companion diagnostics Solid tumors 

分 类 号：R73[医药卫生—肿瘤]